Trial Outcomes & Findings for UltraShape Power for Abdominal Fat and Circumference Reduction (NCT NCT02748928)

NCT ID: NCT02748928

Last Updated: 2019-03-19

Results Overview

Abdominal fat thickness change post UltraShape treatments at 12 weeks follow-up (12wk FU) after final treatment versus baseline

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

62 participants

Primary outcome timeframe

Baseline and 16 weeks (4 weeks treatment + 12 week follow up)

Results posted on

2019-03-19

Participant Flow

Participant milestones

Participant milestones
Measure
Treated and Untreated Abdomen
Circumference and fat thickness reduction of abdomen after Ultrashape treatments (three treatments with U-sculpt Power transducer Isppa 660 W/cm\^2)
Overall Study
STARTED
62
Overall Study
COMPLETED
62
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

UltraShape Power for Abdominal Fat and Circumference Reduction

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Treated and Untreated Abdomen
n=62 Participants
Circumference and fat thickness measurements of abdomen before and after Ultrashape treatments of the same subjects
Age, Continuous
42.5 years
STANDARD_DEVIATION 10.3 • n=5 Participants
Sex: Female, Male
Female
58 Participants
n=5 Participants
Sex: Female, Male
Male
4 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
3 Participants
n=5 Participants
Race (NIH/OMB)
Asian
3 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
1 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
3 Participants
n=5 Participants
Race (NIH/OMB)
White
52 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
Region of Enrollment
United States
62 participants
n=5 Participants
Fat Thickness
31.36 millimeter
STANDARD_DEVIATION 6.44 • n=5 Participants
Midline Circumference
92.14 centimeter
STANDARD_DEVIATION 7.86 • n=5 Participants

PRIMARY outcome

Timeframe: Baseline and 16 weeks (4 weeks treatment + 12 week follow up)

Abdominal fat thickness change post UltraShape treatments at 12 weeks follow-up (12wk FU) after final treatment versus baseline

Outcome measures

Outcome measures
Measure
Treated Abdomen
n=62 Participants
Subjects treated on the abdomen with Ultrashape ultrasound treatments
Change in Abdominal Fat Thickness Compared to Baseline as Measured by Ultrasound
-10.5 percentage change
Standard Deviation 11

SECONDARY outcome

Timeframe: Baseline and at 4, 8, and 12 weeks (from baseline visit)

Population: One participant did not attend the 4 week FU (8 weeks from baseline visit) and three participants did not attend the 8 weeks FU (12 weeks from baseline)

Abdominal fat thickness change as measured by ultrasound post UltraShape Power treatments at 4-week, 8-week and 12-week (from baseline visit) versus baseline

Outcome measures

Outcome measures
Measure
Treated Abdomen
n=62 Participants
Subjects treated on the abdomen with Ultrashape ultrasound treatments
Change in Abdominal Fat Thickness Compared to Baseline as Measured by Ultrasound
Fat thickness change at 4 weeks
-3.2 percentage change
Standard Deviation 8.2
Change in Abdominal Fat Thickness Compared to Baseline as Measured by Ultrasound
Fat thickness change at 8 weeks
-4.3 percentage change
Standard Deviation 8.4
Change in Abdominal Fat Thickness Compared to Baseline as Measured by Ultrasound
Fat thickness change at 12 weeks
-7.0 percentage change
Standard Deviation 9.3

SECONDARY outcome

Timeframe: Baseline and at 4, 8, 12 and 16 weeks (from baseline visit)

Population: One participant did not attend the 4 week FU (8 weeks from baseline visit) and three participants did not attend the 8 weeks FU (12 weeks from baseline)

Abdominal circumference change post UltraShape Power treatments

Outcome measures

Outcome measures
Measure
Treated Abdomen
n=62 Participants
Subjects treated on the abdomen with Ultrashape ultrasound treatments
Change in Abdominal Circumference Compared to Baseline
Abdominal circumference change at 4 weeks
-1.03 centimeter
Standard Deviation 2.19
Change in Abdominal Circumference Compared to Baseline
Abdominal circumference change at 8 weeks
-1.29 centimeter
Standard Deviation 2.64
Change in Abdominal Circumference Compared to Baseline
Abdominal circumference change at 12 weeks
-1.70 centimeter
Standard Deviation 2.52
Change in Abdominal Circumference Compared to Baseline
Abdominal circumference change at 16 weeks
-2.26 centimeter
Standard Deviation 2.70

SECONDARY outcome

Timeframe: 8, 12 and 16 weeks (from baseline visit)

Population: One participant did not attend the 4 week FU (8 weeks from baseline visit) and three participants did not attend the 8 weeks FU (12 weeks from baseline)

Satisfaction assessment will be performed independently by the investigator using a 4-point Likert scale questionnaire from 0 = dissatisfied to 3= very satisfied. The values in the data table reflect the number of Investigators who were "satisfied" or "very satisfied" (i.e., "reported a 2 or 3") with Participant Treatment Outcome, as assessed by the questionnaire.

Outcome measures

Outcome measures
Measure
Treated Abdomen
n=62 Participants
Subjects treated on the abdomen with Ultrashape ultrasound treatments
Number of Investigators Reporting Satisfaction With Participants' Treatment Outcome
Investigator satisfaction rate at 8 week
44 Participants
Number of Investigators Reporting Satisfaction With Participants' Treatment Outcome
Investigator satisfaction rate at 12 week
43 Participants
Number of Investigators Reporting Satisfaction With Participants' Treatment Outcome
Investigator satisfaction rate at 16 week
54 Participants

SECONDARY outcome

Timeframe: 8, 12 and 16 weeks (from baseline visit)

Population: One participant did not attend the 4 week FU (8 weeks from baseline visit) and three participants did not attend the 8 weeks FU (12 weeks from baseline)

Satisfaction assessment will be performed independently by the subjects using a 4-point Likert scale questionnaire from 0 = dissatisfied to 3= very satisfied. The values in the data table reflect the number of participants who were "satisfied" or "very satisfied" (i.e., "reported a 2 or 3") with Treatment Outcome, as assessed by the questionnaire.

Outcome measures

Outcome measures
Measure
Treated Abdomen
n=62 Participants
Subjects treated on the abdomen with Ultrashape ultrasound treatments
Number of Participants Reporting Satisfaction With Treatment Outcome
Subject satisfaction rate at 8 week
47 Participants
Number of Participants Reporting Satisfaction With Treatment Outcome
Subject satisfaction rate at 12 week
42 Participants
Number of Participants Reporting Satisfaction With Treatment Outcome
Subject satisfaction rate at 16 week
46 Participants

SECONDARY outcome

Timeframe: Day 0 (1st treatment), at 2 weeks (2nd treatment) and at 4 weeks (3rd treatment)

Comfort assessment will be performed independently by the subjects using a numerical scale (0-no discomfort to 10-Worst possible discomfort). The subjects will answer this questionnaire after each of the three treatments.

Outcome measures

Outcome measures
Measure
Treated Abdomen
n=62 Participants
Subjects treated on the abdomen with Ultrashape ultrasound treatments
Pain Scale for Rating Discomfort Associated With Treatment
Subject discomfort at first treatment
0.32 score on a scale
Standard Deviation 0.91
Pain Scale for Rating Discomfort Associated With Treatment
Subject discomfort at second treatment
0.25 score on a scale
Standard Deviation 0.70
Pain Scale for Rating Discomfort Associated With Treatment
Subject discomfort at third treatment
0.17 score on a scale
Standard Deviation 0.70

Adverse Events

Treated Abdomen

Serious events: 0 serious events
Other events: 11 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Treated Abdomen
n=62 participants at risk
Subjects treated on the abdomen with Ultrashape ultrasound treatments
Skin and subcutaneous tissue disorders
Welts
14.5%
9/62 • Number of events 9 • Subjects were assessed and followed up for adverse events at each treatment (3 treatments at 2 weeks interval) and at 4 weeks, 8 weeks and 12 weeks after the Ultrashape Power treatment
Skin and subcutaneous tissue disorders
Pruitis / itching
1.6%
1/62 • Number of events 1 • Subjects were assessed and followed up for adverse events at each treatment (3 treatments at 2 weeks interval) and at 4 weeks, 8 weeks and 12 weeks after the Ultrashape Power treatment
Skin and subcutaneous tissue disorders
Blanching
1.6%
1/62 • Number of events 1 • Subjects were assessed and followed up for adverse events at each treatment (3 treatments at 2 weeks interval) and at 4 weeks, 8 weeks and 12 weeks after the Ultrashape Power treatment

Additional Information

Director of Clinical Affairs

Syneron Medical

Phone: +972-73-2442347

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place